Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2071250057) titled 'Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma' on Aug. 4.
Study Type: Interventional
Study Design:
single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
Primary Sponsor: Satomi Natsuko
Condition:
Multiple Myeloma
Intervention:
Multiple doses of etentamig in combination with iberdomide will be explored.
Phase 1: ABBV-383 Dose Escalation
In phase 1 participant...